Samitivej International Children’s Hospital Becomes the First Healthcare Facility in Thailand and Southeast Asia to Introduce the Monoclonal Antibody against RSV for Infants, Launching the ‘Together Against RSV’ Campaign

Samitivej International Children’s Hospital, in collaboration with Sanofi, has officially launched the "Together Against RSV" campaign in Thailand. The initiative is supported by the Pediatric Infectious Disease Society of Thailand (PIDST), the Thai Neonatal Society, and the Royal College of Pediatricians of Thailand (RCPedT). The campaign was inaugurated by H.E. Mr. Jean-Claude Poimboeuf, Ambassador of France to Thailand.

Surangkana Techapaitoon, M.D., Deputy CEO of Samitivej and BNH Hospitals and Director of Samitivej International Children’s Hospital, emphasized the hospital’s commitment to early care and prevention, highlighting its philosophy of ensuring a healthier future for every child. 

Samitivej International Children’s Hospital is the first healthcare facility in Southeast Asia to provide nirsevimab, a ready-to-use monoclonal antibody that offers passive immunity against RSV infection in infants up to two years old. This innovation reduces RSV infection rates by 79.5%, lowers hospitalization risk by 83.2%, and decreases the likelihood of severe cases requiring ICU ventilator support by 75.3%, marking a significant advancement in pediatric medicine.

For more information, contact Samitivej International Children’s Hospital at info@samitivej.co.th